TEXT/SOFT Trials: Analysis of Ovarian Suppression in Breast Cancer

Video

Dr. Pagani, who presented data on the joint analysis of the IBCSG TEXT and SOFT trials at the 2014 ASCO Annual Meeting, discusses how breast cancer patients in these trials responded to different methods of ovarian suppression.

Dr. Pagani, director of the breast unit at the Oncology Institute of Southern Switzerland, presented data on the joint analysis of the IBCSG TEXT and SOFT trials during the Plenary Session at the 2014 ASCO Annual Meeting.

Here she discusses how breast cancer patients in these trials responded to different methods of ovarian suppression, the pros and cons for each of the methods used in the two trials and the resulting side effects, as well as her thoughts on whether the increase in cancer-free survival seen with aromatase inhibitors plus ovarian suppression will result in payers being willing to reimburse for it.

Recent Videos
Developing odronextamab combinations following CAR T-cell therapy failure may help elicit responses in patients with diffuse large B-cell lymphoma.
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Updated results from the 1b/2 ELEVATE study elucidate synergizing effects observed with elacestrant plus targeted therapies in ER+/HER2– breast cancer.
Patients with ESR1+, ER+/HER2– breast cancer resistant to chemotherapy may benefit from combination therapy with elacestrant.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Using bispecific antibodies before or after CAR T-cell therapy in multiple myeloma is an area of education for community oncologists.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Related Content